Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02795884
Recruitment Status : Withdrawn (Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim)
First Posted : June 10, 2016
Last Update Posted : December 30, 2016
Information provided by (Responsible Party):
Yonsei University

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2020